Detalhe da pesquisa
1.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Lancet Haematol
; 8(12): e879-e890, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826411